HUTCHMED CHINA-ADR (HCM)
US44842L1035 - ADR
HCM gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 198 industry peers in the Pharmaceuticals industry. HCM scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. HCM is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year HCM has reported negative net income.
In the past year HCM had a positive cash flow from operations.
In the past 5 years HCM reported 4 times negative net income.
HCM had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of -2.27%, HCM is in the better half of the industry, outperforming 79.49% of the companies in the same industry.
HCM has a Return On Equity of -3.76%. This is amongst the best in the industry. HCM outperforms 82.05% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -2.27% | ||
| ROE | -3.76% | ||
| ROIC | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
HCM has a Gross Margin of 49.54%. This is in the better half of the industry: HCM outperforms 61.03% of its industry peers.
In the last couple of years the Gross Margin of HCM has grown nicely.
HCM does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 49.54% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y46.23%
GM growth 5Y10.56%
2. Health
2.1 Basic Checks
HCM does not have a ROIC to compare to the WACC, probably because it is not profitable.
There is no outstanding debt for HCM. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
An Altman-Z score of 3.93 indicates that HCM is not in any danger for bankruptcy at the moment.
The Altman-Z score of HCM (3.93) is better than 78.97% of its industry peers.
The Debt to FCF ratio of HCM is 16.77, which is on the high side as it means it would take HCM, 16.77 years of fcf income to pay off all of its debts.
HCM has a better Debt to FCF ratio (16.77) than 79.49% of its industry peers.
HCM has a Debt/Equity ratio of 0.05. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of HCM (0.05) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.05 | ||
| Debt/FCF | 16.77 | ||
| Altman-Z | 3.93 |
ROIC/WACCN/A
WACC9.32%
2.3 Liquidity
A Current Ratio of 3.20 indicates that HCM has no problem at all paying its short term obligations.
With a Current ratio value of 3.20, HCM perfoms like the industry average, outperforming 50.26% of the companies in the same industry.
A Quick Ratio of 3.04 indicates that HCM has no problem at all paying its short term obligations.
HCM has a Quick ratio (3.04) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.2 | ||
| Quick Ratio | 3.04 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 86.68% over the past year.
Looking at the last year, HCM shows a very strong growth in Revenue. The Revenue has grown by 88.93%.
Measured over the past years, HCM shows a very strong growth in Revenue. The Revenue has been growing by 31.38% on average per year.
EPS 1Y (TTM)86.68%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q120.12%
Revenue 1Y (TTM)88.93%
Revenue growth 3Y54.33%
Revenue growth 5Y31.38%
Revenue growth Q2Q163.74%
3.2 Future
Based on estimates for the next years, HCM will show a very strong growth in Earnings Per Share. The EPS will grow by 98.86% on average per year.
HCM is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 13.62% yearly.
EPS Next Y-984.33%
EPS Next 2Y-49.83%
EPS Next 3Y98.86%
EPS Next 5YN/A
Revenue Next Year-11.62%
Revenue Next 2Y2.91%
Revenue Next 3Y9.81%
Revenue Next 5Y13.62%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for HCM. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for HCM. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
Compared to the rest of the industry, the Price/Free Cash Flow ratio of HCM indicates a somewhat cheap valuation: HCM is cheaper than 77.44% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 1295.09 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
HCM's earnings are expected to grow with 98.86% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-49.83%
EPS Next 3Y98.86%
5. Dividend
5.1 Amount
HCM does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
HUTCHMED CHINA-ADR
NASDAQ:HCM (4/26/2024, 4:58:01 PM)
After market: 18.675 +0.52 (+2.84%)18.16
-0.83 (-4.37%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap3.10B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -2.27% | ||
| ROE | -3.76% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 49.54% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.58
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.05 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 3.2 | ||
| Quick Ratio | 3.04 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)86.68%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y-984.33%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)88.93%
Revenue growth 3Y54.33%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y